A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
Latest Information Update: 08 Nov 2022
At a glance
- Drugs GDA 201 (Primary) ; Cyclophosphamide; Elotuzumab; Fludarabine; Interleukin-2; Monoclonal antibodies; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- 02 Nov 2022 Status changed from recruiting to completed.
- 14 Dec 2021 Results assessing two year survival data from this study presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2021 Results published in the Gamida-Cell Media Release.